STERIS’ (TSE:STE – Free Report) – Analysts at Cormark upped their FY2025 EPS estimates for STERIS’ in a report issued on Thursday, March 13th. Cormark analyst B. Watson now forecasts that the company will post earnings per share of $0.52 for the year, up from their prior estimate of $0.38. Cormark currently has a “Moderate Buy” rating on the stock. Cormark also issued estimates for STERIS’’s FY2026 earnings at $0.61 EPS.
Separately, Atb Cap Markets upgraded STERIS’ to a “strong-buy” rating in a report on Sunday, December 22nd.
STERIS’ Stock Performance
About STERIS’
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Featured Stories
- Five stocks we like better than STERIS’
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- How to Build the Ultimate Everything ETF Portfolio
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Does a Stock Split Mean?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
